Oral semaglutide reduces cardiovascular event rates in high-risk patients
1. In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in patients with type ...
Tag: semaglutide
Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Semaglutide Improves Outcomes in Metabolic Dysfunction–Associated Steatohepatitis
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Increased Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Among Patients with Diabetes
Click here to read this study in JAMA Ophthalmology. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
![Active smoking cessation intervention may provide tangible results [Project CLIQ]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/smoking-e1418644951268-350x250.jpg)
Semaglutide may aid tobacco cessation in patients with comorbid diabetes
1. In this retrospective study of patients with comorbid type 2 diabetes mellitus and tobacco use disorder (TUD), semaglutide use ...
Novo Nordisk’s Rybelsus demonstrates reduction in cardiovascular events for patients with Type 2 diabetes and cardiovascular disease
Rybelsus in combination with standard T2DM therapy reduced the risk of major cardiovascular events by 14% in patients with diabetes ...
#Visual Abstract: Semaglutide Imrpoves Weight Loss Gains and Pain Related to Knee Osteoarthritis in Patients with Obesity
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Semaglutide reduces heart failure events in patients with preserved ejection fraction
1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
Semaglutide reduces cardiovascular events in patients with atherosclerotic disease and obesity
1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent ...